First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

• Main Authors: Wu, Y-L, Zhou, C.., Liam, Chong-Kin, Wu, G., Liu, X., Zhong, Z., Lu, S., Cheng, Y., How, Soon Hin, ., et al.
• Format: Article
• Language: English; English
• Published: Oxford University Press on behalf of the European Society for Medical Oncology 2015
• Subjects: RC Internal medicine
• Online Access: http://irep.iium.edu.my/44211/2/firstline_erlotinib.pdf; http://irep.iium.edu.my/44211/6/44211_First-line%20erlotinib%20versus%20gemcitabine_SCOPUS.pdf; http://irep.iium.edu.my/44211/; http://annonc.oxfordjournals.org/content/early/2015/06/22/annonc.mdv270.abstract

Background The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Pati...